Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry.

Autor:	Katahira T; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kanazawa A; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Shinohara M; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Koshibu M; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kaga H; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Mita T; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Tosaka Y; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Komiya K; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Miyatsuka T; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Center for Identification of Diabetic Therapeutic Targets, Juntendo University Graduate School of Medicine, Tokyo, Japan., Ikeda F; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Azuma K; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Takayanagi N; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Ogihara T; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Ohmura C; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Miyachi A; Radioisotope and Chemical Analysis Center, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Mie, Japan., Mieno E; Radioisotope and Chemical Analysis Center, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Mie, Japan., Yamashita S; Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Inabe, Mie, Japan., Watada H; Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Center for Identification of Diabetic Therapeutic Targets, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate School of Medicine, Tokyo, Japan.; 6Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Journal of the Endocrine Society [J Endocr Soc] 2018 Oct 26; Vol. 3 (1), pp. 42-51. Date of Electronic Publication: 2018 Oct 26 (Print Publication: 2019).
DOI:	10.1210/js.2018-00142
Abstrakt:	Context: Accurate glucagon level measurements are necessary for investigation of mechanisms for postprandial hyperglycemia in type 2 diabetes. Objective: To evaluate the accuracy of postprandial glucagon level measurements using a sandwich ELISA vs a recently established liquid chromatography-high resolution mass spectrometry (LC-HRMS) method in type 2 diabetes mellitus. Design and Participants: Twenty patients with type 2 diabetes treated with insulin underwent a meal test before and after administration of the dipeptidyl peptidase-4 inhibitor anagliptin for 4 weeks. Blood samples were taken serially after the meal, and glucagon levels were measured using both ELISA and LC-HRMS. We compared the change from baseline to 4 weeks ( Δ 0-4W) using the area under the curve for plasma glucagon during the meal test [area under the curve (AUC)0-3h] measured using ELISA and LC-HRMS. Results: ELISA-based glucagon AUC0-3h was higher than LC-HRMS-based AUC0-3h at baseline and 4 weeks. However, differences in Δ 0-4W-AUC0-3h measured using ELISA and LC-HRMS were not statistically significant. Additionally, Δ 0-4W-AUC0-3h measured using ELISA and LC-HRMS were strongly correlated ( r = 0.87, P < 0.001). Conclusions: Plasma glucagon levels during a meal test in patients with type 2 diabetes measured using ELISA were consistently higher than those measured using LC-HRMS. However, given that the changes in glucagon levels measured using ELISA before and after dipeptidyl peptidase-4 inhibitor therapy were similar to those based on LC-HRMS, this ELISA seems to be useful for evaluating the effect of the drug interventions on postprandial glucagon levels.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu